Asian Journal of Innovation and Policy

Asian Society for Innovation and Policy (아시아기술혁신학회)
권호 표지
DOI QR코드

DOI QR Code

Creation of System Dynamics in an Uncertain and Complex Market: The Case of Korea's Evolving Biopharmaceutical Industry

  • Lee, Jeong Hyop (Innovation Development and Partners) ;
  • Kim, Jaewon (Science Technology and Innovation Policy Institute (STIPI) at King Mongkut's University of Technology Thonburi (KMUTT)) ;
  • Hyeon, Byung-Hwan (Daejeon University)
  • Received : 2019.05.01
  • Accepted : 2019.06.11
  • Published : 2019.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

This article explores the historical evolutionary process of the biopharmaceutical industry of Korea, and how intentional and unintentional policy interventions have triggered the creation of the industry's system dynamics and paved the way for the generation of a few global leading products, including biosimilar, as well as next-generation therapeutics of gene and cell. The policies cover the simple technology transfer of API synthesis to overcome the endemic parasitic disease, new substance patent adoption and new drug development consortia, human resource development, various national initiatives influenced by the Human Genome Project, and venture promotion schemes. The scope and implementation tools under these policies have been aligned and refined to transform traditional fine chemical-based pharmaceuticals, to stimulate large companies' participation and to create technology-based venture companies in the biopharma business of Korea.

Keywords

References

  1. Alsaqabi, S.M. and Lotfy, W.M. (2014) Praziquantel: a review, Journal of Veterinary Science and Technology, Doi:10.4172/2157-7579.1000200.
  2. Annunziata, M. (2016) EY life sciences sector update: Asia-Pacific and Japan, EYGM Limited.
  3. Brendan, M.H. et al. (2014) Korea in the World: Promoting Mutual Understanding and Global Partnerships, Ministry of Foreign Affairs, Korea.
  4. Brill, A. and Robinson, C. (2018) Steps to reducing barriers to biosimilars in the United States, Matrix Global Advisors (MGA).
  5. Business Korea (2018) Investors pour money into Korean biotech ventures, Http://www.businesskorea.co.kr/news/articleView.html?idxno=24681, Accessed on November, 2018.
  6. Dedrick, J. and Kraemer, K.L. (1998) Asia's Computer Challenge: Threat or Oppor-tunity for the United States and the World?, New York: Oxford University Press.
  7. Deloitte (2014) In the Face of Uncertainty: A Challenging Future for Biopharmaceutical Innovation.
  8. Deloitte (2017) A New Future for R&D? Measuring the Return from Pharmaceutical Innovation 2017.
  9. Depret, M. and Hamdouch, A. (2010) Multiscale Clusters and Networks as the Foundations of Innovation Dynamics in the Biopharmaceutical Industry, IDEAS.
  10. Euromonitor (2017) Leading Innovators: South Korea Becomes the Next Stop for Biotechnology, Euromonitor International.
  11. Evaluate Pharma (2017) World preview 2017, Outlook to 2022.
  12. Falk, M.C., Chassy, B.M., Harlander, S.K., Hoban, T.J. and McGloughlin, M.N., et al. (2002) Food biotechnology: benefits and concerns, Journal of Nutrition, 132, 1384-1390. https://doi.org/10.1093/jn/132.6.1384
  13. GE Korea (2015) The Future of Work in Korea, A New Strategy for Growth.
  14. Harrison, M. and Yim, S.V. (2017) War on two fronts: the fight against parasites in Korea and Vietnam, Medical History, 61(3), 401-423. https://doi.org/10.1017/mdh.2017.35
  15. Jagschies, G., Westman, D. and Raw, D. (2014) Supply chain challenges in the biopharmaceutical industry: a case study following the 2011 Tsunami in Japan, Bioprocess International Magazine.
  16. Kenney, M., Han, K. and Tanaka, S. (2004) Venture capital industries, In Shahid, Y.M. and Anjum, A.K. (eds.) Global Change and East Asian Policy Initiatives, Doi.org/10.1596/0-8213-5620-8.
  17. Konde, V. (2009) Secrets to developing a successful biotechnology industry: lessons from developing countries, Asian Biotechnology and Development Review, 11(3), 11-33.
  18. Lücke, J., Wallenstein, J., Kurth, T. and Teichmann, C. (2012) How to plan a success-ful biopharma product rollout, Available at: https://www.bcg.com/publications/2012/biopharmaceuticals-go-to-market-strategy-art-of-launch-how-plan-successful-biopharma-product-rollout.aspx, Accessed on December 2018.
  19. Ministry of Education, Science and Technology of Korea (2009) Biotechnology in Korea, Korea Research Institute of Bioscience and Biotechnology.
  20. Ministry of Science and ICT (2017) The 3rd Biotechnology Fostering Basic Plan.
  21. McKinsey (2018) Asia on the Move: Five Trends Shaping the Asia Biopharmaceutical Market, McKinsey & Company.
  22. Otto, R., Santagostino, A. and Schrader, U. (2014) Rapid Growth in Biopharma: Challenges and Opportunities, McKinsey & Company.
  23. Reich, M. and Govindaraj, R. (1997) Dilemmas in Drug Development for Tropical Diseases: Experiences with Praziquantel, Washington, D.C., USA: The World Bank.
  24. Rhee, S.K. (2003) Challenges and opportunities for biotechnology development: the Korean experiences, In Chaturvedi, S. and Rao, S.R. (eds.) Biotechnology and Development: Challenges and Opportunities for Asia, Research and Information System for the Non-Aligned and Other Developing Countries (RIS).
  25. Schuhmacher, A., Gassmann, O. and Hinder, M. (2016) Changing R&D models in research-based pharmaceutical companies, Journal of Translational Medicine, 14(195), 1-11, Doi: 10.1186/s12967-016-0838-4.
  26. Shah, N. (2004) Pharmaceutical supply chains: key issues and strategies for optimization, Computers and Chemical Engineering, 28, 929-941. https://doi.org/10.1016/j.compchemeng.2003.09.022
  27. Silverman, E. (2004) The 5 most pressing ethical issues in biotech medicine, Biotechnol Healthc, 1(6), 41-46.
  28. Wong, J., Quach, U., Thorsteinsdottir, H., Singer, P.A. and Daar, A.S. (2004) South Korean biotechnology - a rising industrial and scientific powerhouse, Nature Biotech-nology Supplement, 22, 42-47. https://doi.org/10.1038/nbt0104-42
  29. Wong, J. (2011) Betting on Biotech: Innovation and the Limits of Asia's Developmental State, New York: Cornell University Press.
  30. Zika, E., Papatryfon, I., Wolf, O., Gomez-Barbero, M., Stein, A.J. and Bock, A.K. (2007) Consequences, Opportunities and Challenges of Modern Biotechnology for Europe, Luxembourg: European Commission.

Cited by

  1. Divisive Faultlines and Knowledge Search in Technological Innovation Network: An Empirical Study of Global Biopharmaceutical Firms vol.18, pp.11, 2021, https://doi.org/10.3390/ijerph18115614